Fox Run Management, L.L.C. Apellis Pharmaceuticals, Inc. Transaction History

Fox Run Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $841,423 - $1.32 Million	22,102 New	22,102 $847,000
Q4 2023 Feb 13, 2024	SELL	$37.14 - $64.82 $44,493 - $77,654	-1,198 Reduced 18.62%	5,235 $313,000
Q3 2023 Nov 07, 2023	BUY	$23.65 - $89.22 $97,816 - $369,013	4,136 Added 180.06%	6,433 $244,000
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $176,133 - $214,333	2,297 New	2,297 $209,000
Q3 2022 Nov 07, 2022	BUY	$44.76 - $69.66 $484,258 - $753,651	10,819 New	10,819 $739,000

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.34B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.